Description

PRT-060318, also known as PRT318 or P142–76, is a novel selective inhibitor of the tyrosine kinase Syk, as an approach to HIT treatment. PRT318 completely inhibited HIT immune complex-induced aggregation of both human and transgenic HIT mouse platelets. Transgenic HIT model mice were treated with KKO, a mouse monoclonal HIT-like antibody, and heparin. The experimental group received orally dosed PRT318, whereas the control group received vehicle. Nadir platelet counts of PRT318-treated mice were significantly higher than those of control mice. When examined with a novel thrombosis visualization technique, mice treated with PRT318 had significantly reduced thrombosis.

Chemical Structure

Chemical Name

2-(((1R,2S)-2-aminocyclohexyl)amino)-4-(m-tolylamino)pyrimidine-5-carboxamide

SMILES Code

O=C(C1=CN=C(N[C@H]2[C@@H](N)CCCC2)N=C1NC3=CC=CC(C)=C3)N

Theoretical Analysis

XingMo Cat#:XM094  Product Name:PRT-060318  Synonyms:PRT060318; PRT 060318; PRT-060318; PRT318; PRT-318; PRT 318; P14-276.  CAS#:1194961-19-7  Chemical Formula:C18H24N6O  Exact Mass:340.20116  Molecular Weight:340.42

Technical Data

WARNING: This product is for research use only, not for human or veterinary use